2024年全球新药研发趋势

FEBRUARY2024Global Trends in R&D 2024ACTIVITY, PRODUCTIVITY, AND ENABLERS Biomedical advances are transforming healthcare globally. The multi-stakeholder ecosystem that enables this progress has been buffeted by the global COVID-19 pandemic and is resetting and refocusing on future opportunities to advance the understanding of human biology and disease, discover and develop new therapeutics, and provide evidence of the clinical value of these innovations — for individual patients, populations, and health systems. By all of the traditional metrics, including funding levels, numbers of trial starts, drug launches, R&D success rates, and many others, it is clear that industry and investors continue to see tremendous value in the vast array of ongoing research programs around the world. This report assesses the trends in new drug launches and the overall number of initiated clinical trials. It also profiles the state of R&D funding and the activity of companies of different types. The results of research are compared to the input effort in a Clinical Development Productivity Index. The notable acceleration and adaptability of the innovation ecosystem is examined in terms of several enablers of R&D productivity, including the relationship between shortening trial durations and the ‘white space’ within clinical development timelines that have been reducing for some diseases and increasing for others.The research included in this report was undertaken independently by the IQVIA Institute for Human Data Science as a public service, without industry or government funding. The analytics in this report are based on proprietary IQVIA databases and/or third-party information and are not derived from proprietary sponsor trial information.The contributions to this report from Mohit Agarwal, Taskin Ahmed, Chris Bamford, Vaibhav Bhalotia, Tanya Bhardwaj, Lucy Haggerty, Julia Kern, Bhagyashree Nawar, Urvashi Porwal, Tanushree Thakur, and dozens of others at IQVIA are gratefully acknowledged. Find Out MoreIf you wish to receive future reports from the IQVIA Institute for Human Data Science or join our mailing list, visit iqviainstitute.org. MURRAY AITKENExecutive Director IQVIA Institute for Human Data ScienceIntroductionGlobal Trends in R&D 2024: Activity, Productivity, and Enablers©2024 IQVIA and its affiliates. All reproduction rights, quotations, broadcasting, publications reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without express written consent of IQVIA and the IQVIA Institute.REFERENCING THIS REPORTPlease use this format when referencing content from this report:Source: IQVIA Institute for Human Data Science. Global Trends in R&D 2024: Activity, Productivity, and Enablers. February 2024. Available from www.iqviainstitute.org Table of ContentsOverview 2R&D funding 4Clinical trial activity 12New drug approvals and launches 29Clinical development productivity 40Productivity enablers 58Notes on sources 73Methodologies 74 References 75About the authors 76About the Institute 78 OverviewR&D FUNDING R&D funding levels have rebounded in 2023 after a steep decline from the peak seen in 2020-21. While the number of deals has fallen, high profile and high value deals indicate robust interest from investors and innovators in the next generation of therapies. Biopharma funding levels rebounded to $72Bn in 2023, up from $61Bn in 2022, although still well below the levels in 2020-21. M&A activity jumped to $140Bn from $78Bn in 2022, while median deal value dipped for the second year. The leading deal and M&A activity areas related to antibody drug conjugates accounted for 47% of disclosed M&A deals valued over $2Bn and 85% of large oncology deals. Deals involving China-based companies remained significant and AI deals more than doubled. R&D expenditure reported by large pharma corporations totaled a record $161Bn in 2023, an increase of almost 50% since 2018, and historically high at 23.4% of net sales for those companies.CLINICAL TRIAL ACTIVITY Trial starts have slowed to below pre-pandemic levels, reflecting fewer COVID-19activity and shifting research priorities. Clinical trial starts declined 15% in 2023 compared to the prior year and were down 22% from 2021 which included the peak of COVID-19-related trial activity. The three main drivers accounting for the slowdown were fewer COVID-19 trial starts,